导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -12.09% | 3893/4773 |
| 近一周 | -2.54% | 4019/5465 |
| 近一月 | -2.89% | 1992/5421 |
| 近一季 | -2.61% | 1447/5231 |
| 近半年 | -4.11% | 2725/4920 |
| 近一年 | -15.16% | 3703/4394 |
| 近两年 | 31.08% | 2239/2954 |
| 近三年 | 12.58% | 1693/2253 |
| 成立以来 | 24.38% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-14.33% 4641/4961 |
8.95% 2515/5312 |
- - |
- - |
| 2025 | 4.59% 3040/4813 |
-6.42% 3353/3635 |
4.42% 769/4076 |
11.16% 3194/4524 |
-3.72% 3323/4813 |
| 2024 | 28.53% 152/3463 |
-4.64% 1729/2808 |
-7.91% 2141/3014 |
43.04% 27/3129 |
2.32% 960/3463 |
| 2023 | 4.99% 207/2656 |
4.11% 1050/2280 |
-2.71% 637/2385 |
7.84% 24/2515 |
-3.88% 813/2655 |
| 2022 | -24.39% 1213/2207 |
-17.70% 1243/1919 |
2.13% 1344/2016 |
-15.20% 1244/2113 |
6.07% 392/2208 |
| 2021 | 1.93% 647/1822 |
-13.07% 1151/1255 |
7.30% 686/1330 |
6.42% 225/1466 |
2.68% 536/1822 |
| 2020 | 24.88% 627/1250 |
-12.10% 872/1028 |
12.00% 705/1067 |
22.55% 32/1164 |
3.51% 910/1184 |
| 2019 | 42.00% 224/1092 |
44.49% 29/754 |
-6.13% 495/804 |
-4.73% 782/850 |
9.89% 181/918 |
| 2018 | -23.60% 291/834 |
- - |
- - |
- - |
-1.32% 10/691 |
| 2017 | -11.19% 541/714 |
- - |
- - |
- - |
- - |
| 2016 | -17.31% 397/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4546 | 31.90% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.3128 | 30.52% |
| 中欧中证港股通创新药指数发起A | 1.6103 | 30.52% |
| 嘉实中证港股通创新药指数发起式C | 0.8566 | 30.50% |
| 中欧中证港股通创新药指数发起C | 1.4583 | 30.44% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8927 | 30.26% |
| 景顺长城中证港股通创新药ETF联接C | 1.4696 | 29.97% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8736 | 29.94% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8719 | 29.88% |
| 长盛中证证券公司指数(LOF)A VS. 长安沪深300非周期A(740101) |